Our Product Candidates

AVEO Oncology is committed to discovering, developing and commercializing targeted therapies to treat patients with cancer. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. AVEO’s product candidates include AV-203, ficlatuzumab, tivozanib and AV-380.